Actinium Pharmaceuticals (ATNM) Competitors $1.16 -0.06 (-4.92%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ATNM vs. ADAP, PBYI, ELUT, BDTX, TIL, MNPR, TELO, CGEN, GALT, and JATTShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), Elutia (ELUT), Black Diamond Therapeutics (BDTX), Instil Bio (TIL), Monopar Therapeutics (MNPR), Telomir Pharmaceuticals (TELO), Compugen (CGEN), Galectin Therapeutics (GALT), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Adaptimmune Therapeutics Puma Biotechnology Elutia Black Diamond Therapeutics Instil Bio Monopar Therapeutics Telomir Pharmaceuticals Compugen Galectin Therapeutics JATT Acquisition Adaptimmune Therapeutics (NASDAQ:ADAP) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking. Which has higher earnings and valuation, ADAP or ATNM? Actinium Pharmaceuticals has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$175.04M0.90-$113.87M-$0.22-2.80Actinium Pharmaceuticals$81K470.21-$48.82M-$1.39-0.88 Which has more risk and volatility, ADAP or ATNM? Adaptimmune Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Does the media prefer ADAP or ATNM? In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for Adaptimmune Therapeutics and 0 mentions for Actinium Pharmaceuticals. Adaptimmune Therapeutics' average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score. Company Overall Sentiment Adaptimmune Therapeutics Neutral Actinium Pharmaceuticals Neutral Is ADAP or ATNM more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Adaptimmune Therapeutics' return on equity of -74.15% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Actinium Pharmaceuticals N/A -100.85%-47.89% Does the MarketBeat Community believe in ADAP or ATNM? Adaptimmune Therapeutics received 312 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 63.02% of users gave Adaptimmune Therapeutics an outperform vote while only 38.46% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31763.02% Underperform Votes18636.98% Actinium PharmaceuticalsOutperform Votes538.46% Underperform Votes861.54% Do analysts prefer ADAP or ATNM? Adaptimmune Therapeutics currently has a consensus target price of $2.79, suggesting a potential upside of 352.88%. Actinium Pharmaceuticals has a consensus target price of $7.40, suggesting a potential upside of 506.11%. Given Actinium Pharmaceuticals' higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders believe in ADAP or ATNM? 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAdaptimmune Therapeutics beats Actinium Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Ad DarwinAffordable AI Plays: 2 Stocks Under $10 with Huge Potential!As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$38.09M$6.84B$5.14B$19.70BDividend YieldN/A3.06%4.81%3.51%P/E Ratio-0.8810.77135.3043.81Price / Sales470.21284.121,186.5617.72Price / CashN/A56.6540.4221.73Price / Book0.935.374.875.46Net Income-$48.82M$151.75M$118.61M$987.88M7 Day Performance-4.62%-4.72%15.32%-2.19%1 Month Performance-13.72%2.09%15.26%0.78%1 Year PerformanceN/A16.12%34.42%16.53% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.3579 of 5 stars$1.16-4.9%$7.40+537.9%N/A$36.19M$81,000.00-0.8349ADAPAdaptimmune Therapeutics1.5666 of 5 stars$0.59+1.2%$2.79+374.8%+33.2%$150.23M$60.28M-2.64449PBYIPuma Biotechnology4.0845 of 5 stars$3.01+4.5%$7.00+132.6%-25.5%$147.76M$243.57M6.42185Positive NewsELUTElutia2.9808 of 5 stars$4.22+1.9%$10.00+137.0%+114.3%$145.84M$24.75M-1.59180BDTXBlack Diamond Therapeutics2.0423 of 5 stars$2.54-0.8%$15.50+510.2%-7.7%$143.73MN/A-1.9290Positive NewsTILInstil Bio2.9929 of 5 stars$22.01+0.2%$145.00+558.8%+213.9%$143.64MN/A-1.9149MNPRMonopar Therapeutics1.7063 of 5 stars$27.15+7.0%$27.33+0.7%+1,564.2%$143.30MN/A-12.8810TELOTelomir PharmaceuticalsN/A$4.80-7.7%N/AN/A$142.13MN/A0.001High Trading VolumeCGENCompugen2.5258 of 5 stars$1.59-1.2%$4.00+151.6%+110.5%$141.90M$59.85M80.5068Positive NewsGALTGalectin Therapeutics2.3583 of 5 stars$2.26+6.9%$11.00+387.7%+32.5%$141.57MN/A-3.149Options VolumeGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$8.16-24.1%N/A-45.6%$140.76MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Adaptimmune Therapeutics Alternatives Puma Biotechnology Alternatives Elutia Alternatives Black Diamond Therapeutics Alternatives Instil Bio Alternatives Monopar Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Compugen Alternatives Galectin Therapeutics Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ATNM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
